Niki BioSolutions, Inc. - Asset Resilience Ratio
Niki BioSolutions, Inc. (NIKI) has an Asset Resilience Ratio of 0.49% as of March 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Niki BioSolutions, Inc. total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2023)
This chart shows how Niki BioSolutions, Inc.'s Asset Resilience Ratio has changed over time. See NIKI cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Niki BioSolutions, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NIKI current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $102.48K | 0.49% |
| Total Liquid Assets | $102.48K | 0.49% |
Asset Resilience Insights
- Limited Liquidity: Niki BioSolutions, Inc. maintains only 0.49% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Niki BioSolutions, Inc. Industry Peers by Asset Resilience Ratio
Compare Niki BioSolutions, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Galecto Inc
NASDAQ:GLTO |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
ABL Bio Inc
KQ:298380 |
Biotechnology | 0.77% |
Annual Asset Resilience Ratio for Niki BioSolutions, Inc. (2017–2023)
The table below shows the annual Asset Resilience Ratio data for Niki BioSolutions, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $20.64 Million | -- |
| 2022-12-31 | 0.49% | $102.48K | $20.87 Million | -0.59pp |
| 2021-12-31 | 1.08% | $236.62K | $21.91 Million | -63.09pp |
| 2020-12-31 | 64.17% | $28.38 Million | $44.23 Million | +59.74pp |
| 2019-12-31 | 4.44% | $1.06 Million | $23.95 Million | +2.19pp |
| 2018-12-31 | 2.25% | $1.01 Million | $45.07 Million | -4.00pp |
| 2017-12-31 | 6.25% | $1.97 Million | $31.56 Million | -- |
About Niki BioSolutions, Inc.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a r… Read more